U.S. biotech Amgen Inc. provided a 2021 earnings forecast below Wall Street estimates and said the company paused or halted enrollment for clinical trials of three cancer drugs.

Biogen Inc.’s shares slumped as the drugmaker’s chances of getting a regulatory approval for the experimental Alzheimer’s treatment aducanumab suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.

Biogen Inc. showed “exceptionally persuasive” evidence that the company’s experimental Alzheimer’s disease drug aducanumab is effective, U.S. Food and Drug Administration staff said, elevating chances of a swift approval and sending company shares soaring.

Biogen announced the widely awaited submission of a U.S. marketing application for the experimental Alzheimer’s therapy aducanumab, sending the company’s shares up more than 8 percent before the bell.

Shares of Sarepta Therapeutics Inc. soared 32 percent after U.S. regulators shocked Wall Street by reversing their rejection of the muscle-wasting disorder therapy less than four months earlier.

Pfizer Inc. reported a higher-than-expected third-quarter 2019 profit on increased sales of the cancer drug Ibrance and a strong launch of the new heart medicine Vyndaqel.

Eli Lilly third-quarter 2019 sales missed Wall Street estimates as rebates limited revenue from the drug manufacturer’s top-selling diabetes medicine Trulicity, and shares fell about 4 percent.

Biogen Inc. revived plans to seek U.S. approval for the experimental Alzheimer’s treatment aducanumab, surprising investors.

Shares of Sarepta Therapeutics Inc. plunged 14 percent after the U.S. health regulator, in an unexpected move, declined to approve the drugmaker’s newest treatment for a muscle-wasting disorder.

The Trump administration took a step toward allowing the importation of medicines from Canada, an action the president has advocated as a way to bring cheaper Rx drugs to Americans.